在肥胖的老鼠模型中,二烯和洛萨坦会影响ACE-2和IL-6的表达
Andrianto Andrianto1,2, Hanestya O Hermawan1,2, Primasitha M Harsoyo1,2
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Narra J
|September 16, 2024
概括
肥胖会增加心血管疾病的风险. 这项研究发现,洛萨坦和二烯降低了促炎性IL-6,但在肥胖老鼠脂肪组织中增加了ACE2水平.
科学领域:
- 内分泌学 在内分泌学.
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一个与心血管疾病相关的全球健康问题.
- 脂肪细胞表达血管酶转化酶2受体 (ACE2) 和脂肪细胞因子,可能引发细胞因子风暴.
- 升高的IN-6 (IL-6) 与炎症和心血管并发症有关.
研究的目的:
- 为了研究二和洛萨坦对肥胖大鼠脂肪组织中的ACE2和IL-6水平的影响.
- 评估这些药物在调节肥胖相关心血管风险中的炎症和ACE2表达方面的潜力.
主要方法:
- 采用了真实体内实验设计,仅使用测试后的对照组.
- 24只雄性白色大鼠被分为非肥胖 (对照组),肥胖 (未接受治疗),肥胖者接受了林多普利的治疗,肥胖者接受了洛萨坦的治疗.
- 在治疗4周后,使用酶相关免疫吸收试验 (ELISA) 量化了内脏脂肪组织中的ACE2和IL-6水平.
主要成果:
- 洛萨尔坦在肥胖大鼠中显著增加了ACE2水平,与佩林多普利和未经治疗的肥胖对照相比 (分别为p=0.011和p=0.004).
- 与未经治疗的肥胖小鼠组相比,百度普利和洛萨坦都显著降低了肥胖大鼠中的IL-6水平 (分别为p=0.020和p=0.002).
结论:
- 佩林多普利和洛萨坦在管理与肥胖有关的心血管风险方面表现出潜力.
- 这些药物可以抑制像IL-6这样的亲炎性标记物,同时增强脂肪组织中保护性ACE2水平.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:25Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510